

**SCREENING OF NEUROPROTECTIVE SUBSTANCES RELEVANT
TO ALZHEIMER'S DISEASE FROM SEAWEED SPECIES COLLECTED
IN NINH THUAN AND KHANH HOA PROVINCES, VIETNAM**

**Luu Thi Tam¹, Hoang Thi Minh Hien¹, Le Thi Thom¹, Nguyen Cam Ha¹,
Ngo Thi Hoai Thu¹, Nguyen Van Tru¹, Tran Mai Duc²,
Nguyen Thi Minh Hang⁴, Dang Diem Hong^{1,3,*}**

¹Institute of Biotechnology, VAST, Vietnam

²Nha Trang Institute of Technology Research and Application, VAST, Vietnam

³Graduate University of Science and Technology, VAST, Vietnam

⁴Institute of Marine Biochemistry, VAST, Vietnam

Received 14 September 2022; accepted 16 December 2022

ABSTRACT

Currently, nearly 36.5 million people live with Alzheimer's disease worldwide, and acetylcholinesterase inhibition is considered the main treatment strategy against it. Seaweeds (or macroalgae) are a natural source of high-value bioactive compounds and have great potential in the production of health foods/foods, pharmaceuticals, cosmetics, animal feeds, biofertilizers, and biofuels. The most studied and applied seaweed species include red seaweed (Rhodophyta), green seaweed (Chlorophyta) and brown seaweed (Phaeophyta). This study aimed to evaluate the antioxidant and neuroprotective activities of extracts/substances isolated with solvents including ethanol 75° and 96°, water, n-hexane, ethyl acetate under normal and ultrasonic conditions (power 80W, frequency 4.7 kHz and for 1 hour) from 5 economically important seaweed species belonging to genera *Caulerpa*, *Sargassum*, *Gracilaria*, *Ulva* and *Kappaphycus* collected in Ninh Thuan and Khanh Hoa provinces, Vietnam. The results have shown that 05/30 extracts and substances (including SaE96S, SaH, SaHW, SaEA and fucosterol) isolated from five seaweed species exhibited high antioxidant activity through the free radical screening method using 2,2-diphenyl-1-picrylhydrazyl (DPPH) (with EC₅₀ values < 5 mg/mL for extracts and EC₅₀ value < 2 mM for substance) in comparison with positive control ascorbic acid (EC₅₀ = 0.015 mg/mL); acetylcholinesterase inhibitory activity using acetylcholinesterase inhibitor screening KIT (with IC₅₀ values of < 200 µg/mL for both extracts and substances), compared with positive control galantamine (with IC₅₀ value of 52,8 µg/mL). The extracts/substances were able to protect the cell against cytotoxicity in the C6 alzheimer's disease cell model induced by amyloid beta-protein fragment (Aβ₂₅₋₃₅). The results achieved from this research have proven that the extracts/substances isolated from seaweed species were a potential source of medicinal agents for the prevention and treatment of alzheimer's disease.

Keywords: Alzheimer, β amyloid (Aβ₂₅₋₃₅), antioxidant, seaweed, acetylcholinesterase inhibitor.

Citation: Luu Thi Tam, Hoang Thi Minh Hien, Le Thi Thom, Nguyen Cam Ha, Ngo Thi Hoai Thu, Nguyen Van Tru, Tran Mai Duc, Nguyen Thi Minh Hang, Dang Diem Hong, 2022. Screening of neuroprotective substances relevant to Alzheimer's disease from seaweed species collected in Ninh Thuan and Khanh Hoa provinces, Vietnam. *Academia Journal of Biology*, 44(4): 33–45. <https://doi.org/10.15625/2615-9023/17512>

*Corresponding author email: ddhong60vn@yahoo.com

©2022 Vietnam Academy of Science and Technology (VAST)

INTRODUCTION

Alzheimer's disease (AD) is a neurological disorder that affects millions of elderly people worldwide (Li et al., 2018). According to the report, across the globe, it is estimated that around 35 million people live with Alzheimer's disease and approximately 65 million develop dementia by 2030 (Prince et al., 2013). AD is the most common age-related neurodegenerative disorder that is characterized by redox imbalance in neurons, cholinergic impairment, aggregation of senile plaques, and neurofibrillary tangles due to the presence of β -amyloid ($A\beta$) peptide and hyperphosphorylation of tau protein (Tau is the major microtubule-associated protein (MAP) of a normal mature neuron). The increased phosphorylation of tau reduces their biological activity. Neurodegenerative diseases with abnormal tau inclusions are referred to as tauopathies (including Alzheimer's disease (AD) other tauopathies) in which the brain is from three to four-fold more hyperphosphorylated than the normal adult's brain, enhancing glutamate stimulation may induce the neuroinflammation and neuronal degeneration, resulting in learning, cognitive decline and memory loss (Feng & Wang, 2012; Mendiola-Precoma et al., 2016). Until now, there is no cure completely for AD due to the complexity of neuropathological mechanisms involved in the disease's development and progression (Graham et al., 2017). AD treatment has mainly focused on the early detection and prevention of the disease. Brand-name drugs used in the treatment and management of AD (including rasagiline, rivastigmine, and donepezil) are primarily associated with the inhibition of cholinesterase and β -secretase (BACE-1) enzymes (Cortés et al., 2015; Vassar, 2011). However, they may have side effects, such as nausea, vomiting, hepatotoxicity, digestive disorders (Ali et al., 2015). Therefore, the potential future direction for AD treatment is to use nutrient-rich nature products with neuroprotective activity, which have few or no side-effects compared to synthetic drugs (Olasehinde et al., 2017).

Seaweeds (or macroalgae) are marine organisms and have been employed as a natural source of highly bioactive compounds. Among them, a few seaweed species could grow in harsh habitats and release some valuable secondary metabolites. Seaweed extracts have been proven to possess strong antioxidant properties (Corsetto et al., 2020), hepatoprotective effects (Hira et al., 2017) and inhibitory activities on Hela cell proliferation (Lee et al., 2021), antibacterial activities (Fayzi et al., 2020) and antiviral activities (Lomartire et al., 2022). Therefore, seaweed has long been utilized as a source of foods (such as vegetables, and salads), herbs to treat tumors, urinary disorders, gastrointestinal problems, coughs, boils, hemorrhoids, tumors, asthma, goiter and headache (Dang et al., 2007; Dang & Hien, 2004; Niazi et al., 2011).

To obtain highly bioactive seaweed extracts, it is necessary to select suitable separation solvents for each species. The extraction yield of the targeted bioactive compounds is solvent-dependent and different solvents can be used according to the polarity and location of those compounds. An aqueous solvent is suitable for the separation of polysaccharides, while phenolics and carotenoids are usually extracted with organic solvents. In most cases, the extracts obtained with organic solvents appear more bioactive, while it has been confirmed that extracts derived from polar solvents have higher antibacterial activity. When the bioactive extracts are targeted for neutral pharmaceutical, and food industries, the solvents are limited, and must also be non-toxic. Ethanol, water, and their mixtures are ideal solvents for the production of extracts with high antioxidant capacity (Pappou et al., 2017).

The neuroprotective effects of bioactive substances from some seaweeds against neurodegenerative disorders have been reported by Alghazwi et al. (2016). Olasehinde et al. (2019b) have also indicated that crude extracts and substances isolated from seaweeds have neuroprotective effects

against AD through cholinesterase inhibition pathways. The ethanol/water extracts rich in phlorotannins, phenolic acids, and flavonoids isolated from *Ecklonia maxima*, *Gelidium pristoides*, *Gracilaria gracilis* and *Ulva lactuca* had acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities. Furthermore, sulfated polysaccharides found in *Ulva rigida* and the aforementioned seaweeds also exhibited strong inhibitory effects toward BChE and AChE *in vitro* models (Olasehinde et al., 2019a). Pang et al. (2022) also reported that ethanol extract of *Gracilaria manilaensis* inhibited cholinesterase enzyme with an EC₅₀ value of 3.77 ± 0.20 mg/mL. This suggested that seaweeds are an important marine organism source of highly bioactive substances/compounds with neuroprotective properties against Alzheimer's disease-associated pathology.

Currently, in Vietnam, a total of 827 species of seaweed including 412 species of red seaweed (Rhodophyta), 180 species of green seaweed (Chlorophyta), 147 species of brown seaweed (Ochrophyta-Phaeophytaceae) and 88 species of cyanobacteria (Cyanophyta) have been identified (Phang et al., 2016; Dang et al., 2019, Dang & Ha, 2022). Among them, species of *Caulerpa*, *Sargassum*, *Gracilaria*, *Ulva* and *Kappaphycus* genera are economically important seaweed species of Vietnam with significant reserves, currently being cultivated and exploited on large scale. Therefore, the extraction and screening of the compounds/substances which was capable of neuroprotective activities have practical significance and have been considered to be highly feasible in exploiting substances with neuroprotective properties and memory enhancement from the seaweeds. In this study, we evaluated the neuroprotective properties of the extracts/substances isolated from species of Vietnam seaweed through antioxidant activity, inhibition of enzyme acetylcholinesterase (AChE) and protective effect against cytotoxicity in Alzheimer's disease cell model induced by A β ₂₅₋₃₅ on the C6 neuronal cell line.

MATERIALS AND METHODS

Materials, chemicals

Seaweeds: The seaweed species of the genera *Sargassum*, *Caulerpa*, *Kappaphycus*, *Ulva* and *Gracilaria* were collected in the sea waters of Ninh Thuan and Khanh Hoa provinces, Vietnam from February to April 2022. After collection, the species of seaweed were transferred to the laboratory, then removed from dirt, and sandy soil, gently dried at room temperature and under low light and stored in a refrigerator at -20 °C until use. The cell morphology and scientific name of the seaweed species used in this study were shown in Figure 1.

Cell line: C6 glioma cell line was obtained from the American Type Culture Collection (ATCC®; cat. no. CCL-107).

Chemicals: DPPH (2,2-diphenyl-1-picrylhydrazyl, purity 95%, Alfa Aesar, Japan); acetylthiocholine iodide (ACTI) (SigmaAldrich, Singapore); 5-5'-dithiobis-2-nitrobenzoic acid (DTNB) (SigmaAldrich, Singapore), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Invitrogen, USA), A β ₂₅₋₃₅ (purity $\geq 97\%$, No. A.4559; Sigma, USA), Galantamine hydrobromide (SoPharma AD, Bulgaria). Chemicals used for cell culture: Dulbecco's Modified Eagle Medium (DMEM)/high glucose, Fetal bovine serum (FBS), penicillin and streptomycin (Invitrogen, USA) and other common chemicals were used in this study.

Methods

Isolation of seaweed extracts

To study the pharmacological effects of seaweed species, the biomass of selected seaweeds was extracted using solvents including warm water 60 °C (denoted as W), ethanol 75° (denoted as E75) and 96° (denoted as E96); n-hexane (denoted as H), n-hexane-water (denoted as HW) and ethyl acetate (denoted as EA) on a magnetic stirrer with different extraction conditions: extraction time from 2–9 hours; the ratio of biomass to solvent (w/v) from 1:2 to 1:5;

seaweed extraction without or in combination with ultrasound using an ultrasonic bath (BioBase, ultrasonic power 80 w, ultrasonic time 1 hour, ultrasonic frequency 4.7 kHz, denoted as S). After the extraction process, the samples were filtered through filter papers and concentrated by a vacuum evaporator to

recover the total extracts. Particularly in the n-hexane fraction of *Sargassum* species, three pure substances were isolated and identified fucosterol ($C_{29}H_{48}O$), saringosterol ($C_{29}H_{48}O_2$) and allitol ($C_6H_{14}O_6$). All extracts/substances obtained were used as raw feedstock for bioactive evaluation.




Figure 1. Cell morphology of seaweed species collected from the sea waters of Ninh Thuan and Khanh Hoa provinces in 2022. a. *Ulva reticulata* (Forssk), 1775; b. *Kappaphycus alvarezii* (Doty) Doty bown; c. *Gracilaria salicornia* (C. Agardh) E. Y. Dawson; d. *Caulerpa lentillifera* J. Agardh, 1837; e. *Sargassum mcclurei* Setchell, 1933

Determination of the antioxidant activity of total extracts/substances from seaweed using the DPPH method

The free radical scavenging ability of the extracts/substances was tested by 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay as described by Sharma & Bhat (2009). The reaction mixture consisted of 100 μ L of DPPH (at a concentration of 0.2 μ M) and 100 μ L of ethanol/water/n-hexane/ethyl acetate extracts from seaweed species (at concentrations of 0, 0.4, 2 and 10 mg/mL) or substances (fucosterol, saringosterol, allitol) at a concentration of 0.1, 0.5 and 2 mM. The reaction mixture was

incubated in the dark at room temperature for 30 min; then the absorbance of the DPPH was measured by spectrophotometer. DPPH produces purple color in methanol solution and fades to shades of yellow color (2,2-diphenyl-1-picrylhydrazine (DPPH-H) in the presence of antioxidants. DPPH radical scavenging capacity of antioxidants is evaluated by the decrease in the absorbance at the wavelength of 517 nm. Ascorbic acid (at the concentrations investigated of 4, 20, and 100 μ g/mL) was used as the positive control.

The percentage of DPPH radical scavenging activity (SA) was calculated by the following equation:

$$\%SA = \left\{ \left(OD_{\text{control}} - OD_{\text{reagent samples}} \right) / OD_{\text{control}} \right\} * 100$$

In which: OD_{control}: Absorbance of the control;
OD_{reagent samples}: Absorbance of the extracts/substances.

EC₅₀ value (half maximal effective concentration) is calculated based on the standard curve of $y = ax + b$. The EC₅₀ value is inversely proportional to the free radical scavenging activity/antioxidant property of the sample.

Determination of protective activity against cytotoxicity in alzheimer's disease cell model induced by Aβ₂₅₋₃₅ on the C6 cell line

This method is performed according to the detailed description in the publication of Yu et al. (2019). 100 μL of C6 neuron cells were seeded in a 96-well plate at an initial cell density of 1×10^5 cells/mL and cultured for 24 hours. After that, the old medium was removed, 100 μL of DMEM medium with 1 μL of DMSO solution or 1 μL of

extracts/substances (at concentrations of 50 and 100 μg/mL)/galantamine (at a concentration of 100 μg/mL) were added and the cells were continued to culture for 24 hours. To detect the effect of Aβ₂₅₋₃₅, cells were treated with Aβ₂₅₋₃₅ at concentrations of 20 μM for 2 hours. The experiment consisted of 3 groups: the Control group (DMSO - Aβ₂₅₋₃₅); the model group (DMSO + Aβ₂₅₋₃₅); experimental group (extracts/substances/galantamine + Aβ₂₅₋₃₅). Each experimental formula was performed at least in triplicate. Then, 5 μL of MTT (5 mg/mL) was added and incubated for 4 hours in the dark. After that, 100 μL of DMSO was added and the plate was shaken on a shaker for 20 min. The absorbance of each well at a wavelength of 570 nm was detected by an automatic microplate analyzer. The cell survival fraction was calculated according to the equation:

$$\% \text{ of alive cells} = \left[OD_{570 \text{ nm experimental}} / OD_{570 \text{ nm control}} \right] \times 100$$

Determination of acetylcholinesterase (AChE) inhibitory activity

The inhibitory effect of AChE (Sigma Aldrich, Singapore) of the sample was carried out using the Acetylcholinesterase Inhibitor Screening Kit (MAK324, Sigma, USA) according to the manufacturer's instructions. This method is based on the following principle: The substrate of acetylthiocholine iodide (ACTI) is hydrolyzed by the catalysis of AChE to produce thiocholin. The product of thiocholin reacts rapidly with a reagent of DTNB and a yellow compound of 5-thio-2-nitro benzoic acid is formed. The amount of this yellow compound is proportional to the AChE activity. Evaluation of AChE activity was based on the measurement of the absorbance of the samples at a wavelength of 412 nm. A detail of the procedure is following: a Reaction mix consisting of

154 μL assay buffer; 1 μL substrate, 0.5 μL DTNB was mixed thoroughly and used within 30 minutes. 5 μL of the test solution at the different concentrations and 45 μL of 0.4 IU/mL AChE reference Enzyme were added to the wells. The control (No Enzyme) consisted of 5 μL DMSO and 45 μL assay buffer, the no inhibitor control consisted of 5 μL of DMSO and 45 L of 0.4 IU/mL AChE reference Enzyme. Galantamine (at a concentration of 100 μg/mL) was used as a positive control. The mixture was mixed well and incubated for 15 minutes at room temperature. Then, 150 μL of the Reaction mixture was added into the corresponding wells and the absorbance at a wavelength of 412 nm was measured at 0 min and 10 mins. Each reagent concentration was repeated 3 times. The results were evaluated through the percentage of AChE inhibition (%) according to the formula:

$$I\% = (1 - \Delta OD_{\text{test}} / \Delta OD_{\text{No inhibitor}}) \times 100\%$$

Where: I%: Percentage of AchE inhibition;
 ΔOD_{test} : Change in $OD_{412\text{nm}}$ value of wells with extracts/substances at 0 min and 10 min;
 $\Delta OD_{\text{No inhibitor}}$: Change in $OD_{412\text{nm}}$ of wells with no inhibitor control at 0 min and 10 min.

Statistical analysis

Data were expressed by mean \pm standard deviation ($X \pm SD$) using Microsoft excel 2013 software. The differences among the sample were assessed using a one-way analysis of variance (ANOVA) at the significance level of $p < 0.05$.

RESULTS AND DISCUSSION

Antioxidant activity of extracts/substances from seaweeds

Antioxidant activity of 30 extracts/substances obtained using solvents as aqueous, ethanol, n-hexane, and ethyl acetate from 5 seaweed species including *Sargassum mcclurei* (Sa), *Caulerpa lentillifera* (C), *Ulva reticulata* (U), *Kappaphycus alvarezii* (K) and *Gracilaria salicornia* (G) have been evaluated for their ability to scavenge DPPH (2,2-diphenyl-1-picrylhydrazyl) free radicals. The antioxidant activity and percentage of free radical neutralization of extracts/substances obtained from selected seaweeds using the DPPH method were shown in Table 1 and Figure 2A.

The results in Table 1 showed that among a total of 30 extracts/substances isolated from 5 seaweed species belonging to the genera *Sargassum*, *Caulerpa*, *Ulva*, *Kappaphycus*, and *Gracilaria*, 9 samples exhibited antioxidant activity at tested concentrations including 4 extracts from *U. reticulata* (UWS, UE96S, UE75, UE75S) and 5 extracts isolated from *S. mcclurei* (including 4 extracts (SaE96S, SaH, SaEA, SaHW) and 1 substances (fucosterol). Extracts isolated from genera *Caulerpa*, *Kappaphycus* and *Gracilaria* did not show antioxidant activity at the tested concentrations. The antioxidant capacity of the extracts/substances was demonstrated by the EC_{50} value (Fig. 2B).

The lowest values of EC_{50} represent the highest antioxidant capacity and vice versa. The results are in Figure 2B. showed that the EC_{50} values of 9 screened samples ranged from 0.63 to 5.70 mg/mL, of which the *Sargassum* extracted with ethyl acetate (SaEA) and n-hexane/aqueous (SaHW) indicated the best antioxidant capacity, with EC_{50} values of 0.63 mg/mL and 0.68 mg/mL, respectively, followed by fucosterol (with an EC_{50} value of 0.70 mg/mL or 1.7 mM) compared to the positive control, ascorbic acid ($EC_{50} = 0.015$ mg/mL). Some studies have confirmed that alcoholic solutions and/or hydrophilic solvent mixtures provide extracts with better antioxidant activity. This can be attributed to the selective extraction of polar chemical substances, such as phenolic compounds, that exhibit significant antioxidant capacity (Pappou et al., 2017). Ethanolic and aqueous extracts may contain several components such as saponins, terpenoid, cardiac glycoside, phlobatamin, phenolic, and flavonoids that have been reported to have high antioxidant activity and depend on seaweed species, location as well as seaweed harvest season of the year (Sobuj et al., 2021). In our study, different solvents (water, ethanol, n-hexane, ethyl acetate, and a mixture of ethanol/water with the ratio of 75:25 (v/v) were tested to evaluate antioxidant activity. The alcohol and aqueous extracts of *Sargassum* and *Ulva* exhibited high antioxidant activity possibly due to: water being the best solvent for phenolic compounds and the ethanolic mixture for carotenoid extraction. Using pure ethanol resulted in lower solvation of phenolics, while carotenoids exhibited a better extraction ability in between that of water and the ethanol/water mixture (Pappou et al., 2017).

As published by Prasedya et al. (2019), the ethanol extract of *Ulva lactuca* exhibited relatively high antioxidant activity, with EC_{50} values ranging from 0.50 mg/mL to 0.68 mg/mL. The ethanol extract of

Sargassum polycystum exhibited antioxidant activity with an EC₅₀ value of 98 ppm (equivalent to 98 µg/mL) as reported by Safitri et al. (2021). Thus, the results on the antioxidant activity of the respective extracts

in our study were lower than those reported above. This difference may be due to differences in seaweed species of each region, harvest season, extraction solvent as well as extraction methods used in the study.

Table 1. Antioxidant activity of aqueous/ethanol/n-hexane/ethyl acetate extracts/substances of 5 seaweed species collected from Ninh Thuan and Khanh Hoa provinces, Vietnam using DPPH radical scavenging assay

	Constituents	<i>Sargassum mcclurei</i>	<i>Ulva reticulata</i>	<i>Ulva alvarezii</i>	<i>Caulerpa lentillifera</i>	<i>Gracilaria salicornia</i>
Extracts	Hot water (W)	-	-	-	nd	nd
	Hot water + sonication (WS)	-	+	-	nd	nd
	Ethanol 75% (E75)	-	+	-	nd	nd
	Ethanol 75% + Sonication (E75S)	-	+	-	-	-
	Ethanol 96% (E96)	-	-	-	nd	nd
	Ethanol 96% + Sonication (E96S)	+	++	-	-	-
	n-hexane (H)	++	nd	nd	nd	nd
	Ethyl acetate (EA)	++	nd	nd	nd	nd
	n-hexane/water (HW)	+++	nd	nd	nd	nd
Substances	Fucosterol	+				
	Saringosterol	-				
	Allitol	-				

Notes: -: Negative; +: weak activity; ++: Moderate activity; +++: strong activity; nd: not determined.




Figure 2. DPPH free radical scavenging ability (%) (a) and EC₅₀ values (b) of aqueous/ethanol/n-hexane/ethyl acetate extracts/substances of *Ulva reticulata*, *Sargassum mcclurei*. Ascorbic acid was test at concentration of 4, 20, and 100 µg/mL), fucosterol - at concentration of 0.1, 0.5 and 2 mM

Protective activity against cytotoxicity in alzheimer’s disease cell model induced by Aβ₂₅₋₃₅ on the C6 cell line

In AD patients, deposition of Aβ₂₅₋₃₅ has been shown to have a direct toxic effect on neurons, it may enhance the sensitivity of neurons to harmful factors such as free

radicals and oxidative stress, thus leading to neuronal apoptosis (Ma et al., 2013). Therefore, the inhibition of neuronal apoptosis induced by the Aβ₂₅₋₃₅ protein provides a feasible method for the prevention and treatment of AD (Yu et al., 2019). In this study, we also evaluated the cytoprotective

effect of 9 potential extracts/substances against the $A\beta_{25-35}$ - induced cytotoxicity on

cell line C6. The obtained results were shown in Figure 3.




Figure 3. Cytotoxicity (a) and protect cell against cytotoxicity in C6 alzheimer's disease cell model induced by amyloid beta - protein fragment ($A\beta_{25-35}$) (b) of extracts/substances from seaweeds. Cells were grouped as follows: the control group (untreated), the model group (cells were treated with 20 μM $A\beta_{25-35}$ for 2 hours to establish the AD cell model), and the test groups (cells were pretreated with extracts/substances from seaweeds and fucoesterol at 50 and 100 $\mu\text{g}/\text{mL}$ for 24 hours and then with 20 μM $A\beta_{25-35}$ for 2 hours). Cell survival was analyzed with the MTT assay. Note: * $p < 0.05$ comparison of different concentrations of the test groups and the model group

The results in Figure 3A showed that all nine aqueous and alcohol extracts of *U. reticulata* (including UWS, UE96S, UE75, and UE75S) and *S. mclurei* (including SaE96S, SaH, SaEA, SaHW, and fucoesterol) were not cytotoxic at all tested concentrations (50–100 $\mu\text{g}/\text{mL}$). There was no significant difference between the control and the experiment groups in the survival rate of the C6 cell line ($p > 0.05$).

The results in Figure 3B showed that when C6 cells were induced by $A\beta_{25-35}$, the cell survival rate decreased to 66% compared with the control formula (cells were left untreated, and the survival rate was 100%). The addition of extracts/substances from genera *Ulva* and *Sargassum* at different concentrations positively affected the survival rate of C6 cells. Among the 9 samples tested, 5/9 samples had the effect of protecting C6 cells against toxicity when cells were induced by $A\beta_{25-35}$, including *Sargassum* extracted with ethanol 96° combined with ultrasound (SaE96S), n-hexane (SaH), ethyl acetate (SaEA), n-hexane/aqueous (SaHW) and fucoesterol. The extracts from *Ulva* did not

show protective activity on C6 cells against $A\beta_{25-35}$ - induced toxicity at the tested concentrations. Two samples of SaEA and SaHW showed very good cytoprotective activity with the survival rate of C6 cells of $93.7 \pm 1.85\%$ and $104.9 \pm 0.97\%$ respectively which were higher than 27.7% and 38.9% compared with the model group (DMSO + $A\beta_{25-35}$), respectively. Furthermore, the cytoprotective effect on C6 cells in these two formulations was even higher than that of galantamine (used as a positive control) at a concentration of 100 $\mu\text{g}/\text{mL}$ in an AD model. The SaH, SaE96S extracts and fucoesterol substance showed lower protective activity, with C6 cell survival rates of $71.13 \pm 0.36\%$; $77.61 \pm 1.24\%$ and $69 \pm 0.58\%$, respectively. These values are higher than 5.13, 11.61, and 3% compared with the corresponding values in the model group. Research by Oh et al. (2018) showed that fucoesterol isolated from *Ecklonia stolonifera* was effective in reducing neurotoxicity induced by oligomers amyloid in neuronal cell line models (Oh et al., 2018). Fucoesterol from *Padina australis* was evaluated for its neuroprotective effects in

SH-SY5Y cells treated with A β ₂₅₋₃₅; activation of the down-regulation of amyloid precursor protein (APP) expression (Alghazwi et al., 2018). Choi et al. (2017) also reported that ethanol extract of *S. serratifolium* reduced the accumulation of β -amyloid (A β ₁₋₄₂) in the cell line CHO-751 (Chinese hamster ovary cells). Our obtained results were also similar to the above statement.

AchE inhibitory activity of extracts/substances from seaweeds

AchE inhibitory activities of 9 screened potential extracts/substances were shown in Figure 4. According to Vinutha et al. (2017), plant extracts/substances with strong or weak AchE inhibitory effects were classified based on their percentage of AchE inhibition. Potential inhibitors (AchE inhibition \geq 50%), moderate inhibitors (AchE inhibition of 30–50%) and weak inhibitors (AchE inhibition \leq 30%) have

been proposed and recognized. On that basis, the percentage of AchE inhibition of the seaweed extracts/substances and the positive control galantamine at the tested concentration of 100 μ g/mL shown in Figure 4. indicated that 4/9 seaweed extracts were moderate AchE inhibitors, including UE96S (44.12%); SaE96S (41.88%), SaHW (41.19%) and SaEA (36.21%). UWS, UE75, UE75S, SaH, and fucosterol were weak AchE inhibitors, with AchE inhibition percentages of only 8.3; 12.7; 14.6; 29.97 and 22.3%, respectively. AchE inhibitory activity of the positive control galantamine reached 76.4% (with an IC₅₀ value of 52.8 μ g/mL). Compared with the positive control galantamine, IC₅₀ values of seaweed extracts as UE96S; SaE96S; SaHW; SaEA; UWS, UE75, UE75S, SaH and fucosterol were lower, reaching 161.01; 157.22; 156.68; 180.33; 1034.22; 586.98; 478.58; 283.61 μ g/mL and 250 μ M, respectively.




Figure 4. AchE inhibitory activities (a) and IC₅₀ value (b) of seaweed extracts. AchE inhibition activity of 9 extracts/substance (fucosterol) from seaweeds *Ulva* and *Sargassum* at 100 μ g/mL with galantamine (100 μ g/mL) as the positive control.

Data are expressed as the mean \pm SD (n = 3)

Acetylcholinesterase inhibitors have been identified as an important therapeutic strategy for the management of alzheimer's disease. High acetylcholinesterase activity is associated with cholinergic dysfunction and memory impairment in AD. This is due to the rapid hydrolysis of acetylcholine - an important neurotransmitter responsible for sending nerve impulses from one nerve cell to another. Thus, inhibiting AchE increased the

availability of acetylcholine, and improved neuronal transmission and memory function. The AchE inhibitory effect found in *Sargassum* and *Ulva* extracts/substances in our study will be the basis for the application of seaweeds in the control of AD. According to Syad et al. (2013), petroleum ether, n-hexane, benzene, dichloromethane, chloroform, and acetone extracts isolated from *Sargassum wightii* Greville at a concentration

of 100 $\mu\text{g/mL}$ exhibited AchE inhibitory effect of $100 \pm 5.9\%$; $87.21 \pm 6.62\%$; $82.58 \pm 1.18\%$; $43.82 \pm 1.2\%$ and $63.68 \pm 3.4\%$, with IC_{50} values of 19.33 ± 0.56 ; 46.81 ± 1.62 ; 27.24 ± 0.90 ; 50.56 ± 0.90 ; 70.90 ± 1.07 and $69.58 \pm 3.55 \mu\text{g/mL}$, respectively. Natarajan et al. (2009) also reported that the methanol extract of *Sargassum* had AchE inhibitory activity with an IC_{50} value of 1 mg/mL. Castro-Silva et al. (2019) also reported that fucosterol isolated from *Sargassum horridum* had a strong inhibitory effect on AchE. The polysaccharides from *Ulva lactuca* have been proven effective in AchE inhibition with an IC_{50} value of $106.93 \pm 1.45 \mu\text{g/mL}$ (Olasehinde et al., 2019b). Our results are also similar to the above study. However, the AchE inhibitory effect of the extracts/substances isolated from *Sargassum mcclurei* and *Ulva lentillifera* in this study was lower than that of other publications. The cause may be due to differences in seaweed species and extraction conditions, leading to differences in composition and substances present in the obtained seaweed extracts.

Acetylcholinesterase (AChE) inhibition and antioxidant activity are considered to be highly correlated with Alzheimer's disease treatment. Antioxidant compounds might be implicated in AChE inhibition. Recent studies bound Alzheimer's disease to an inflammatory process induced by reactive oxygenated substances. The oxidative stress intervenes, for a share, in the physiopathology of neuronal degeneration (Ferreira et al., 2006). The multifactorial nature of AD suggests that a multi-targeted therapeutic approach might be more advantageous than single-target drugs and combination therapies. Some of the AChE inhibitor molecules currently being evaluated in clinical studies, such as memantine targets different additional pathways of AD by exhibiting antioxidant functions, acting as a β -secretase inhibitor, preventing A β aggregation, and influencing tau hyperphosphorylation. Natural drug candidates with anti-amyloidogenic and antioxidant properties in addition to cholinesterase inhibitory activity could be

regarded as having special potential and need to focus on research to produce drugs for AD for human use in the short term coming (Mathew & Subramanian, 2014).

From the obtained results, there were 8 total crude extracts and 1 substance having a neuroprotective activity that met 2–3 screening criteria, including UWS, UE96S, UE75, UE75S (isolated from *U. reticulata*) and SaE96S, SaH, SaHW, SaEA and fucosterol (isolated from *S. mcclurei*). Which, there were 04 total crude extracts and 01 potential fucosterol from the *S. mcclurei* that had neuroprotective effects based on all 3 criteria used for screening. These are only preliminary results, we need to continue to elucidate the molecular mechanism of these extracts/substance in *in vitro* models as well as evaluate acute and subchronic oral toxicity *in vivo* experimental animal models. The obtained research will be presented in the further publication by the research team.

CONCLUSION

The results of screening seaweed extracts with neuroprotective activity showed that in total 30 extracts from 5 seaweed species including *S. mcclurei*, *C. lentillifera*, *U. reticulata*, *K. alvarezii* and *G. salicornia* collected in Ninh Thuan and Khanh Hoa provinces, we have selected 5 potential extracts/substances isolated from the seaweed species *S. mcclurei* (such as SaE96S, SaH, SaHW, SaEA and fucosterol) with three good pharmacological properties as antioxidant activity, AchE inhibitory activity and cytoprotective activity against toxicity induced by amyloid β -protein fragment 25–35 on the neuronal C6 cell line. Thus, *S. mcclurei* is potential seaweed with neuroprotective effects against Alzheimer's disease.

Acknowledgements: The project was funded by the project "Neuroprotective effects on Alzheimer's disease (AD) of some seaweed species in Vietnam" with code VAST04.10/22–23 for Prof. Dr. Dang Diem Hong.

REFERENCES

- Alghazwi M., Kan Y. Q., Zhang W., Gai W. P., Garson M. J., Smid S., 2016. Neuroprotective activities of natural products from marine macroalgae during 199-2015. *J. Appl. Phycol.*, 28: 3599–3616.
- Alghazwi M., Smid S., Zhang W., 2018. *In vitro* protective activity of South Australian marine sponge and macroalgae extracts against amyloid beta ($A\beta_{1-42}$) induced neurotoxicity in PC-12 cells. *Neurotoxicol. Teratol.*, 68: 72–83.
- Ali T. B., Schleret T. R., Reilly B. M., Chen W. Y., Abagyan R., 2015. Adverse effects of cholinesterase inhibitors in Dementia, according to the pharmacovigilance databases of the United-States and Canada. *PLoS One*, 10: 0144337.
- Castro-Silva E. S., Bello M., Hernandez-Rodriguez M., Correa-Basurto J., Murillo-Alvarez J.I., Rosales-Hernandez M.C., Munoz-Ochoa M., 2019. *In vitro* and *in silico* evaluation of fucosterol from *Sargassum horridum* as potential human acetylcholinesterase inhibitor. *J. Biomol. Struct. Dyn.*, 37(12): 3259–3268.
- Choi M. W., Jung C. G., Kim H. R., Kim R. I., 2017. Effect of *Sargassum serratifolium* Extracts on β -Amyloid Production. *Korean J. Fish Aquat. Sci.*, 50(1): 085–091.
- Corsetto P. A., Montorfano G., Zava S., Colombo I., Ingadottir B., Jonsdottir R., Sveinsdottir K., Rizzo A. M., 2020. Characterization of antioxidant potential of seaweed extracts for enrichment of convenience food. *Antioxidants (Basel)*, 19(3): 249.
- Cortés A., Gracia E., Moreno E., Mallol J., Lluís C., Canela E. I., Casadó V., 2015. Moonlighting adenosine deaminase: a target protein for drug development. *Med. Res. Rev.*, 35: 85–125.
- Dang Diem Hong and Nguyen Cam Ha, 2022. Chapter Title: Seaweeds of Vietnam: Opportunities for commercial production. Chapter 7 - Volume 1. In Book: Sustainable global resources of seaweeds. Springer Publishing Company, pp. 109–127.
- Dang D. H., Anh H. T. L., Thom L. T., Ha N. C., Tien D. D., Duy D. A., 2019. The genus *Gracilaria* in Vietnam. Institute of Ocean and Earth Sciences Monograph Series 17: Taxonomy of Southeast Asian Seaweed III. Phang, Song & Lim (eds): 29–46.
- Dang D. H., Hien H. M., Son P. N., 2007. Seaweeds from Vietnam used for functional food, medicine and biofertilizer. *J. Appl. Phycol.*, 19: 817–826.
- Dang D. H., Hien H. T. M., 2004. Nutritional analysis of Vietnamese seaweeds for food and medicine, No Title. *Biofactors*, 22: 323–325.
- Fayzi L., Askarne L., Cherifi O., Boufous E. H., Cherifi K., 2020. Comparative antibacterial activity of some selected seaweed extracts from Agadir coastal regions in Morocco. *Intl J. Curr. Microbiol. Appl. Sci.*, 9: 390–399.
- Feng Y., Wang X., 2012. Antioxidant therapies for Alzheimer's disease. *Oxid. Med. Cell Longev.*, 2012: 472932.
- Ferreira A., Proença C., Serralheiro M. L. M., Araujo M. E. M., 2006. The *in vitro* screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. *J. Ethnopharmacol.*, 108(1): 31–37.
- Mendiola-Precoma J., Berumen L. C., Padilla K., Garcia-Alcocer G., 2016. Therapies for prevention and treatment of alzheimer's disease. *Biomed. Res. Int.*, 2016: 2589276.
- Graham W.V., Bonito-Oliva A., Sakmar T.P., 2017. Update on Alzheimer's disease therapy and prevention strategies. *Annu. Rev. Med.*, 68: 413–430.
- Hira K., Sultana V., Ara J., Haque S. E., 2017. Protective role of *Sargassum* species in liver and kidney dysfunctions and associated disorders in rats intoxicated

- with carbon tetrachloride and acetaminophen. *Pak. J. Pharm. Sci.*, 30(3): 721–728.
- Lee H., Selvaraj B., Lee J. W., 2021. Anticancer effects of seaweed-derived bioactive compounds. *Appl. Sci.*, 11: 11261.
- Li X., Wang H., Long J., Pan G., He T., Anichtchik O., Belshaw R., Albani D., Edison P., Green E. K., Scott J., 2018. Systematic analysis and biomarker study for alzheimer's disease. *Sci Rep.*, 8(1): 17394.
- Lomartire S., Gonçalves A. M. M., 2022. Antiviral activity and mechanisms of seaweeds bioactive compounds on enveloped viruses-A Review. *Mar. Drugs*, 20(6): 385.
- Ma W. W., Hou C. C., Zhou X, Yu H. L., Xi Y. D., Ding J., Zhao X., Xiao R., 2013. Genistein alleviates the mitochondria-targeted DNA damage induced by β -amyloid peptides 25–35 in C6 glioma cells. *Neurochem Res.*, 38(7): 1315–1323.
- Mathew M., Subramanian S., 2014. *In vitro* screening for anti-cholinesterase and antioxidant activity of methanolic extracts of Ayurvedic Medicinal plants used for cognitive disorders. *PLoS ONE*, 9(1): e86804.
- Natarajan S., Shanmugiahthevar K. P., Kasi P. D., 2009. Cholinesterase inhibitors from *Sargassum* and *Gracilaria gracilis*: Seaweeds inhabiting South Indian coastal areas (Hare Island, Gulf of Mannar). *Nat. Prod. Res.*, 23: 355–69.
- Niazi A. K., Kalra S., Irfan A., Islam A., 2011. Thyroidology over the ages. *Indian J. Endocrinol. Metab.*, 15: 121–126.
- Oh J. H., Choi J. S., Nam T., 2018. Fucosterol from an edible brown alga *Ecklonia stolonifera* prevents soluble amyloid beta-induced cognitive dysfunction in aging rats. *Mar. Drugs*, 16: 368.
- Olasehinde T. A., Mabinya L. V., Olaniran A. O., Okoh A. I., 2019a. Chemical characterization, antioxidant properties, cholinesterase inhibitory and anti-amyloidogenic activities of sulfated polysaccharides from some seaweeds. *Bioact. Carbohydr. Diet. Fibre*, 18: 100182.
- Olasehinde T. A., Olaniran A. O., Okoh A. I., 2019b. Macroalgae as a valuable source of o bioactive compounds for the treatment of Alzheimer's disease. *Mar. Drugs*, 17: 609.
- Pang J. R., How S. W., Wong K. H., Lim S. H., Phang S. M., Yow Y. Y., 2022. Cholinesterase inhibitory activities of neuroprotective fraction derived from red alga *Gracilaria manilaensis*. *Fi. . Aquat. Sci.*, 25(2): 49–63.
- Olasehinde T. A., Olaniran A. O., Okoh A. I., 2017. Therapeutic potentials of microalgae in the treatment of Alzheimer's disease. *Molecules*, 22: 480.
- Pappou, S., Dardavila, M. M., Savvidou, M. G., Louli, V., Magoulas, K., Voutsas, E., 2017. Extraction of bioactive compounds from *Ulva lactuca*. *Appl. Sci.*, 12: 2117. <https://doi.org/10.3390/app12042117>
- Phang S. W., Yeong H. Y., Ganzon-Fortes E.T., Lewmanomont K., Prathep A., Le N.H., Gerung G.S., Tan K.S., 2016. Marine algae of the South China Sea bordered by Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. *Raffles Bull. Zool. Suppl.*, 34: 13–59.
- Prasedya E.S., Ni W. R. M, Rizkia A., Sipti M., Rizka A. F., Haji S., 2019. Antioxidant activity of *Ulva lactuca* L. from different coastal locations of Lombok Island, Indonesia. In: AIP Conference Proceedings. *AIP Publishing LLC*, pp. 020003.
- Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C. P., 2013. The global prevalence of dementia: A systematic review and metaanalysis. *Alzheimers Dement* 9: 63.e2–75.e2.
- Safitri I., Warsidah W., Mega S. J. S., Arie A. K., Novi Sumarni T., 2021. Total phenolic

- content, antioxidant and antibacterial activities of *Sargassum polycystum* of ethanol extract from waters of Kabung Island. *Berkala Sainstek*, 9(3): 139–145.
- Sharma O. P., Bhat T. K., 2009. DPPH antioxidant assay revisited. *Food Chem.*, 113(4): 1202–1205.
- Sobuj M. K. A., Islam M., Mahmud Y., Rafiquzzaman S. M., 2021. Effect of solvents on bioactive compounds and antioxidant activity of *Padina tetrastromatica* and *Gracilaria tenuistipitata* seaweeds collected from Bangladesh. *Scientific Reports*, 11(1): 1–13.
- Syad A.N., Shunmugiah K.P., Kasi P.D., 2013. Antioxidant and anti-cholinesterase activity of *Sargassum wightii*. *Pharm. Biol.*, 51(11): 1401–1410.
- Vassar R., 2011. BACE1 inhibitor drugs in clinical trials for alzheimer's disease. *Alzheimer's Res. Ther.* 6: 89.
- Vinutha B., Prashanth D., Salma K., Sreeja S.L., Pratiti D., Padmaja R., Radhika S., Amit A., Venkateshwarlu K., Deepak M., 2007. Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory activity. *J. Ethnopharmacol.*, 109: 359–363.
- Yu X., Li Y., Mu X., 2019. Effect of quercetin on PC12 alzheimer's disease cell model induced by A β 25-35 and its mechanism based on Sirtuin1/Nrf2/HO-1 pathway. *BioMed Res. Int.*, 2020: 8210578.